当前位置：
X-MOL 学术
›
Lancet Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Risk-based treatment of non-rhabdomyosarcoma soft-tissue sarcoma in children.
The Lancet Oncology ( IF 41.6 ) Pub Date : 2019-11-27 , DOI: 10.1016/s1470-2045(19)30679-5 Javier Martin-Broto 1
The Lancet Oncology ( IF 41.6 ) Pub Date : 2019-11-27 , DOI: 10.1016/s1470-2045(19)30679-5 Javier Martin-Broto 1
Affiliation
|
The age-standardised incidence of soft-tissue sarcoma in children aged 0–14 years is 9 per million person-years, with non-rhabdomyosarcoma soft-tissue sarcoma (NRSTS) constituting 50–60% of cases. Paediatric NRSTS has been prospectively reported in only a few studies, and has not been systematically addressed in the way that rhabdomyosarcoma has been since the inception of the Intergroup Rhabdomyosarcoma Study (IRS) in 1972. Although synovial sarcomas and malignant peripheral nerve sheath tumours account for nearly 60% of NRSTS, there are many different NRSTS subtypes. This heterogeneity in NRSTS, along with the small number of cases in the paediatric population compared with the adult population, has hindered a more comprehensive systematic approach for risk classification and treatment allocation.
中文翻译：
儿童非横纹肌肉瘤软组织肉瘤的基于风险的治疗。
0-14岁儿童的年龄标准化软组织肉瘤发病率为每百万人年9例，非横纹肌肉瘤软组织肉瘤（NRSTS）占病例的50-60％。儿科NRSTS仅在少数研究中得到前瞻性报道，并且自1972年组间横纹肌肉瘤研究（IRS）以来就没有以横纹肌肉瘤的方式系统地解决过。尽管滑膜肉瘤和恶性周围神经鞘瘤占了原因近60％的NRSTS，有许多不同的NRSTS亚型。NRSTS的这种异质性，以及与成人相比，儿科人群的病例数少，阻碍了更全面的系统化风险分类和治疗分配方法。
更新日期：2020-01-04
中文翻译：
儿童非横纹肌肉瘤软组织肉瘤的基于风险的治疗。
0-14岁儿童的年龄标准化软组织肉瘤发病率为每百万人年9例，非横纹肌肉瘤软组织肉瘤（NRSTS）占病例的50-60％。儿科NRSTS仅在少数研究中得到前瞻性报道，并且自1972年组间横纹肌肉瘤研究（IRS）以来就没有以横纹肌肉瘤的方式系统地解决过。尽管滑膜肉瘤和恶性周围神经鞘瘤占了原因近60％的NRSTS，有许多不同的NRSTS亚型。NRSTS的这种异质性，以及与成人相比，儿科人群的病例数少，阻碍了更全面的系统化风险分类和治疗分配方法。
京公网安备 11010802027423号